Derm Fall Clinical

Real-world analysis comparing systemic therapies show dupilumab better improves EASI and quality of life among affected children.

Data from the ongoing TARGET-DERM AM observational study show patients with more exposed disease have generally worse severity and challenges linked to quality of life.

The JAK inhibitor received FDA approval for vitiligo this summer. Investigator now see it as a potent non-steroidal option for eczema.

Christopher Bunick, MD, discusses the future progress of acne management—including a potential mRNA vaccine current in development.

The novel OX40 inhibitor showed significant efficacy in 4 different doses versus placebo in Fall Clinical Dermatology data.

With a broadening array of drug options, involving patients in the care process may be a key to adherence and long-term success.

Christopher Bunick, MD, PhD, reviews the benefit of antibiotic resistance, blood-brain barrier penetration, and digestive distress with agents like sarecycline.

Peter Lio, MD, explains firsthand how abrocitinib and upadacitinib became the latest options for his most difficult-to-treat patients.

Investigators called for prospective studies with longer time horizons to see if these associations persist throughout childhood.

To the investigators’ knowledge, the study offers insights into lesion presentations on undiagnosed adults with vitiligo.

Investigators said that patient-reported outcomes from the 2 abrocitinib groups showed greater efficacy than the dupilumab and placebo groups.

Respondents suggested that increasing product availability and demonstrating the consequences of sunburn could increase sun protection among young people.

Dr. Elewski hopes that in the future more clinicians will prescribe biologics such as secukinumab and etancercept for the treatment of psoriasis.

Though not all hemangioma last past 10 years old in pediatric patients, some untreated hemangioma are associated with high risk of ulceration.

Though Dr. Khattri felt the diagnosis of psoriatic arthritis had been “stagnant”, the inclusion of biologic therapies and more has been a welcomed change.

Certain biologics such as infliximab have aided psoriasis patients in the mitigation of symptoms from the COVID-19 virus.

Dr. Swanson also details the effects of the COVID-19 pandemic on her practice with the implementation of telemedicine.

Dr. Desai says that Janus kinase inhibitors present a new mechanism of action, with effects on cytokine signals that signal inflammation in atopic diseases.

Dr. Elewski speaks of the safety and efficacy of several new and developing therapies, including bimekizumab treatment which has yet to be approved in the United States.

Swanson noted the efficacy and safety of dupilumab, which she feels revolutionized patient care.

Dr. Khattri speaks of the benefits of diagnosing the condition early in psoriasis patients, as well as what dermatologists can do before referring a patient to a rheumatologist.

New therapies are breaking ground in the world of vitiligo research, which Dr. Desai believes will result in FDA approvals in the coming years.